SIGNIFICANCE OF CYTOGENETIC ABNORMALITIES IN PATIENTS WITH POLYCYTHEMIA VERA

Yazar: Sever, Matjaz, Quintás-Cardama, Alfonso, Pierce, Sherry, Zhou, Lingsha, Kantarjian, Hagop, Verstovsek, Srdan
Baskı/Yayın Bilgisi 2013

Comparison of thalidomide and lenalidomide as therapy for myelofibrosis

Yazar: Jabbour, Elias, Thomas, Deborah, Kantarjian, Hagop, Zhou, Lingsha, Pierce, Sherry, Cortes, Jorge, Verstovsek, Srdan
Baskı/Yayın Bilgisi 2011

Patients with Polycythemia Vera and Essential Thrombocythemia with Prior Malignancy Do Not Have Significantly Worse Outcome

Yazar: Cherry, Mohamad, Cardenas-Turanzas, Marylou, Pham, Hannah, Kantarjian, Hagop, Cortes, Jorge, Pierce, Sherry, Zhou, Lingsha, Verstovsek, Srdan
Baskı/Yayın Bilgisi 2013

Increased likelihood of post-polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities

Yazar: Benton, Christopher B, Tanaka, Maria, Wilson, Catherine, Pierce, Sherry, Zhou, Lingsha, Cortes, Jorge, Kantarjian, Hagop, Verstovsek, Srdan
Yayımlandı Leuk Res (2015)

Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Post–Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

Yazar: Tam, Constantine S., Kantarjian, Hagop, Cortes, Jorge, Lynn, Alice, Pierce, Sherry, Zhou, Lingsha, Keating, Michael J., Thomas, Deborah A., Verstovsek, Srdan
Yayımlandı J Clin Oncol (2009)

Prognostic Value of Blasts in Peripheral Blood in Myelofibrosis in the Ruxolitinib Era

Yazar: Masarova, Lucia, Bose, Prithviraj, Pemmaraju, Naveen, Daver, Naval G., Zhou, Lingsha, Pierce, Sherry, Sasaki, Koji, Kantarjian, Hagop, Estrov, Zeev, Verstovsek, Srdan
Yayımlandı Cancer (2020)

Modest Activity of Pomalidomide in Patients with Myelofibrosis and Significant Anemia

Yazar: Daver, Naval, Shastri, Aditi, Kadia, Tapan, Quintas-Cardama, Alfonso, Jabbour, Elias, Konopleva, Marina, O’Brien, Susan, Pierce, Sherry, Zhou, Lingsha, Cortes, Jorge, Kantarjian, Hagop, Verstovsek, Srdan
Yayımlandı Leuk Res (2013)

Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis

Yazar: Daver, Naval, Cortes, Jorge, Newberry, Kate, Jabbour, Elias, Zhou, Lingsha, Wang, Xuemei, Pierce, Sherry, Kadia, Tapan, Sasaki, Koji, Borthakur, Gautam, Ravandi, Farhad, Pemmaraju, Naveen, Kantarjian, Hagop, Verstovsek, Srdan
Yayımlandı Haematologica (2015)

Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs

Yazar: Masarova, Lucia, DiNardo, Courtney D., Bose, Prithviraj, Pemmaraju, Naveen, Daver, Naval G., Kadia, Tapan M., Chifotides, Helen T., Zhou, Lingsha, Borthakur, Gautam, Estrov, Zeev, Konopleva, Marina, Verstovsek, Srdan
Yayımlandı Blood Adv (2021)

A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis

Yazar: Bose, Prithviraj, Swaminathan, Mahesh, Pemmaraju, Naveen, Ferrajoli, Alessandra, Jabbour, Elias J., Daver, Naval G., DiNardo, Courtney D., Alvarado, Yesid, Yilmaz, Musa, Huynh-Lu, Julie, Qiao, Wei, Wang, Xuemei, Matamoros, Aurelio, Zhou, Lingsha, Pierce, Sherry, Schroeder, Kurt D., Kantarjian, Hagop M., Verstovsek, Srdan
Yayımlandı Leuk Lymphoma (2019)

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis

Yazar: Masarova, Lucia, Verstovsek, Srdan, Hidalgo-Lopez, Juliana E., Pemmaraju, Naveen, Bose, Prithviraj, Estrov, Zeev, Jabbour, Elias J., Ravandi-Kashani, Farhad, Takahashi, Koichi, Cortes, Jorge E., Ning, Jing, Ohanian, Maro, Alvarado, Yesid, Zhou, Lingsha, Pierce, Sherry, Gergis, Romany, Patel, Keyur P., Luthra, Rajyalakshmi, Kadia, Tapan M., DiNardo, Courtney D., Borthakur, Gautam, Bhalla, Kapil, Garcia-Manero, Guillermo, Bueso-Ramos, Carlos E., Kantarjian, Hagop M., Daver, Naval
Yayımlandı Blood (2018)